DBV Technologies (DBVT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DBV Technologies (DBVT) has a cash flow conversion efficiency ratio of -0.518x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-83.08 Million) by net assets ($160.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see DBV Technologies (DBVT) market capitalisation for the company's overall valuation and market capitalisation.
DBV Technologies - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how DBV Technologies's cash flow conversion efficiency has evolved over time, based on yearly financial data.
DBV Technologies Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DBV Technologies ranked by their cash flow conversion efficiency. See DBV Technologies (DBVT) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Biglari Holdings Inc
NYSE:BH
|
0.039x |
|
Shentong Technology Group Co Ltd
SHG:605228
|
0.058x |
|
Dor Alon
TA:DRAL
|
0.005x |
|
Omnijoi Media Corp
SHE:300528
|
0.124x |
|
Shanghai Zhongzhou Special Alloy Materials Co. Ltd.
SHE:300963
|
-0.045x |
|
V V Food & Beverage Co Ltd
SHG:600300
|
0.083x |
|
Golden Entertainment Inc
NASDAQ:GDEN
|
0.062x |
|
Shenzhen MinDe Electronics Technology Ltd
SHE:300656
|
0.020x |
Annual Cash Flow Conversion Efficiency for DBV Technologies (2011–2025)
The table below shows the annual cash flow conversion efficiency of DBV Technologies from 2011 to 2025. View today's stock price for DBV Technologies for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $168.77 Million | $-121.18 Million | -0.718x | +81.18% |
| 2024-12-31 | $27.39 Million | $-104.47 Million | -3.815x | -571.38% |
| 2023-12-31 | $140.19 Million | $-79.65 Million | -0.568x | -98.36% |
| 2022-12-31 | $194.45 Million | $-55.70 Million | -0.286x | +73.79% |
| 2021-12-31 | $99.03 Million | $-108.24 Million | -1.093x | -35.63% |
| 2020-12-31 | $205.49 Million | $-165.61 Million | -0.806x | -4.95% |
| 2019-12-31 | $193.19 Million | $-148.35 Million | -0.768x | +31.83% |
| 2018-12-31 | $165.78 Million | $-186.74 Million | -1.126x | -28.02% |
| 2017-12-31 | $182.88 Million | $-160.91 Million | -0.880x | -258.89% |
| 2016-12-31 | $267.90 Million | $-65.68 Million | -0.245x | -195.04% |
| 2015-12-31 | $384.24 Million | $-31.93 Million | -0.083x | +53.34% |
| 2014-12-31 | $182.22 Million | $-32.45 Million | -0.178x | +45.72% |
| 2013-12-31 | $74.09 Million | $-24.31 Million | -0.328x | -23.20% |
| 2012-12-31 | $66.84 Million | $-17.80 Million | -0.266x | +49.14% |
| 2011-12-31 | $19.79 Million | $-10.36 Million | -0.524x | -- |
About DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobu… Read more